Nonadherence to LLT associated with higher healthcare resource utilization and costs in a large integrated healthcare delivery system in Southern California.

Matthew T Mefford, Rachelle Juan, Teresa N Harrison, Alejandro Victores, Lori D Bash, Ronald D Scott, Kristi Reynolds, Jaejin An

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matthew T MeffordDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.

Rachelle JuanDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.

Teresa N HarrisonDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.

Alejandro VictoresMerck & Co., Inc., Rahway, NJ, USA.

Lori D BashMerck & Co., Inc., Rahway, NJ, USA.

Ronald D ScottKaiser Permanente West Los Angeles Medical Center, Los Angeles, CA, USA.

Kristi ReynoldsDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.

Jaejin AnDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Guideline-recommended lipid-lowering therapy (LLT) can reduce healthcare utilization and costs for patients with and at-risk for atherosclerotic cardiovascular disease (ASCVD). We examined healthcare utilization and associated costs among adult LLT users in Kaiser Permanente Southern California ≥21 years of age having ASCVD or intermediate (≥7.5% to <20%) or high (≥20%) 10-year ASCVD risk between 2015 and 2021. LLT adherence trajectories were determined using group-based trajectory modeling over 12 months. All-cause and ASCVD-related annualized adjusted costs were calculated through 2023. High versus low LLT adherence was associated with lower all-cause costs (-$999; 95% CI: -$1100, -$897) and varied across subgroups by ASCVD risk. Adults missing a follow-up low-density lipoprotein cholesterol (LDL-C) measure had +$8312 (95% CI +$7955, +$8669) higher all-cause costs compared to adults with LDL-C < 55 mg/dL. Improving LDL-C management through optimized LLT treatment strategies can reduce economic burdens in high-risk patients.

Indexed as

Atherosclerotic cardiovascular diseaseCostHealthcare resource utilizationLipid-lowering therapyLow density lipoprotein-cholesterol

Identifiers

PMID42876524

DOI10.1016/j.ahjo.2026.100751

PMCPMC13661205

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.